Strengthened Commercial Execution Driving Topline Growth
■ Continued Progress Across R&D Pipeline
■ Expanded Programs On Track to Deliver Net Cost Savings Targets
NEW YORK, Tuesday, August 5, 2025 — Pfizer Inc. (NYSE: PFE) reported financial results for the second
quarter of 2025 and reaffirmed its 2025 Revenue guidance while raising guidance(1) for Adjusted(2) diluted EPS.
EXECUTIVE COMMENTARY
Dr. Albert Bourla, Chairman and CEO of Pfizer:
“Pfizer had another strong quarter of focused execution and we’re pleased with our progress in advancing our
R&D pipeline, driving our commercial performance and expanding our margins. We continue to strengthen
our company for the future and we’re confident in our ability to create further value for patients and our
shareholders.”
David Denton, CFO and EVP of Pfizer:
“Our robust second-quarter Revenue and EPS performance demonstrates our continued focus on commercial
execution and operational efficiency. We raised our full-year 2025 Adjusted diluted EPS guidance,
demonstrating confidence in our ability to execute against our strategic priorities and deliver strong results for
shareholders.”
OVERALL RESULTS
■ Second-Quarter 2025 Revenues of $14.7 Billion, Representing 10% Year-over-Year Operational Growth
■ Second-Quarter 2025 Reported(3) Diluted EPS of $0.51, and Adjusted(2) Diluted EPS of $0.78
■ Reaffirms Full-Year 2025 Revenue Guidance(1) in a Range of $61.0 to $64.0 Billion
■ Raises Full-Year 2025 Adjusted(2) Diluted EPS Guidance(1) by $0.10 to a Range of $2.90 to $3.10, which
Absorbs a One-Time Impact of Approximately $0.20 Related to 3SBio Transaction
■ On Track to Deliver Approximately $7.2 Billion in Overall Anticipated Net Cost Savings from Previously
Announced Cost Improvement Initiatives(4) by End of 2027, Driving Productivity Gains and Operating Margin
Expansion
